Paclitaxel and spirulina co-loaded polymeric nanoparticles: in-vitro and in-vivo anticancer study

Paclitaxel spirulina nanoparticles were said to have promising anticancer activity against gastric cancer. Nanoparticles of paclitaxel-spirulina were prepared for treating gastric cancer using precipitation technique. The synergistic anticancer efficiency againstMKN45 cells retains when the paclitaxel and spirulina were encapsulated into nanoparticles. To increase the site specific delivery, intra-tumoral administration was carried in the in vivo evaluation. There was an increase in overall survival in an MKN45-transplanted mice model and notable improvement in anti-tumour efficacy when paclitaxel-spirulina nanoparticles were delivered through intra-tumoral administration. The further investigation of overall anticancer mechanism of these nanoparticles is made as a major part in this research. Hence, the conjecture of this research is that, the paclitaxel-spirulina encapsulated nanoparticles could be an effective chemotherapeutic formulation for gastric cancer.

据报道，紫杉醇-螺旋藻纳米粒（paclitaxel spirulina nanoparticles）对胃癌具有颇具潜力的抗癌活性。本研究采用沉淀法（precipitation technique）制备该纳米粒以用于胃癌治疗。当紫杉醇与螺旋藻被包封为纳米粒后，其对MKN45细胞的协同抗癌效能得以保留。为提升靶向递送效果，本研究在体内评价（in vivo evaluation）中采用瘤内给药（intra-tumoral administration）方式。在MKN45细胞移植瘤小鼠模型（transplanted mice model）中，小鼠总生存期（overall survival）得到延长；且通过瘤内给药递送紫杉醇-螺旋藻纳米粒时，抗肿瘤功效（anti-tumour efficacy）得到显著改善。本研究的核心内容为对这类纳米粒的整体抗癌机制开展深入探究。因此，本研究提出如下假设：包封紫杉醇与螺旋藻的纳米粒有望成为一种有效的胃癌化疗制剂（chemotherapeutic formulation）。